Edition:
United States

Karo Pharma AB (KARO.ST)

KARO.ST on Stockholm Stock Exchange

36.85SEK
11 Dec 2018
Change (% chg)

-0.15kr (-0.41%)
Prev Close
37.00kr
Open
36.85kr
Day's High
36.90kr
Day's Low
36.65kr
Volume
608,930
Avg. Vol
1,351,410
52-wk High
39.40kr
52-wk Low
25.25kr

Chart for

About

Karo Pharma AB, formerly known as Karo Bio AB, is a Sweden-based biopharmaceutical company engaged in the research and development of drugs based on the nuclear receptors. The Company’s pipeline comprises three projects: Estrogen Receptor Beta (ERbeta) cancer, a platform, which focuses on the development of ERbeta in cancer... (more)

Overall

Beta: 0.71
Market Cap(Mil.): kr3,270.22
Shares Outstanding(Mil.): 82.17
Dividend: 0.28
Yield (%): 0.70

Financials

  KARO.ST Industry Sector
P/E (TTM): 20.39 92.25 33.63
EPS (TTM): 1.95 -- --
ROI: 11.70 0.29 15.02
ROE: 15.82 0.94 16.60

Karo Pharma says Chairman Anders Lonner has died

STOCKHOLM, Dec 3 Speciality pharma firm Karo Pharma's Chairman Anders Lonner has died, the company said in a statement on Sunday evening.

Dec 03 2018

Deals of the day-Mergers and acquisitions

Oct 29 The following bids, mergers, acquisitions and disposals were reported by 2000 GMT on Monday:

Oct 29 2018

Private equity firm EQT launches $654 million cash bid for Sweden's Karo Pharma

STOCKHOLM Private equity firm EQT on Monday made a recommended 5.97 billion Swedish crown ($654 million) cash bid to buy Swedish specialty pharma group Karo Pharma.

Oct 29 2018

Private equity firm EQT launches $654 mln cash bid for Sweden's Karo Pharma

STOCKHOLM, Oct 29 Private equity firm EQT on Monday made a recommended 5.97 billion Swedish crown ($654 million) cash bid to buy Swedish specialty pharma group Karo Pharma.

Oct 29 2018

Earnings vs. Estimates